(CercleFinance.com) – Wells Fargo reaffirms its ‘overweight’ recommendation on Johnson & Johnson (J&J) despite a price target lowered from $178 to $170, based on a ratio of approximately 15 times its 2025 EPS assumption for the health group.
As the December 5 investor day approaches, the broker says it expects the focus to be on the medium- and long-term outlook for pharmaceuticals and medical technologies, particularly growth in 2025 and beyond. beyond that in pharmaceuticals.
Copyright © 2023 CercleFinance.com. All rights reserved.
The information and analyzes distributed by Cercle Finance only constitute a decision-making aid for investors. Cercle Finance cannot be held responsible directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional advisor before making any investment. This indicative information does not in any way constitute an inducement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends using the buttons below.